133 related articles for article (PubMed ID: 29596526)
1. ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
Montavon Sartorius C; Schoetzau A; Kettelhack H; Fink D; Hacker NF; Fedier A; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2018; 13(3):e0195213. PubMed ID: 29596526
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and prognostic value of femoral lymph node metastasis in FIGO stage III vulvar carcinoma.
Tu H; Sun P; Gu HF; Zhang XK; Huang H; Wan T; Liu JH
Eur J Surg Oncol; 2017 Sep; 43(9):1768-1775. PubMed ID: 28602173
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection.
Hanprasertpong J; Jiamset I; Atjimakul T
Tumour Biol; 2016 Jun; 37(6):7421-30. PubMed ID: 26678885
[TBL] [Abstract][Full Text] [Related]
6. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience.
Kempf E; Desamericq G; Vieites B; Diaz-Padilla I; Calvo E; Estevez P; Garcia-Arreza A; Martinez-Maestre MA; Duran I
Clin Transl Oncol; 2017 Feb; 19(2):173-179. PubMed ID: 27193130
[TBL] [Abstract][Full Text] [Related]
8. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma.
Viswanathan AN; Pinto AP; Schultz D; Berkowitz R; Crum CP
Gynecol Oncol; 2013 Sep; 130(3):545-9. PubMed ID: 23747330
[TBL] [Abstract][Full Text] [Related]
9. The impact of plasma fibrinogen levels on patients with vulvar cancer.
Seebacher V; Polterauer S; Grimm C; Tempfer C; Hefler-Frischmuth K; Reinthaller A; Hefler L
Eur J Obstet Gynecol Reprod Biol; 2012 Mar; 161(1):88-91. PubMed ID: 22310943
[TBL] [Abstract][Full Text] [Related]
10. The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer.
Fukumoto K; Taniguchi T; Usami N; Kawaguchi K; Fukui T; Ishiguro F; Nakamura S; Yokoi K
J Epidemiol; 2015; 25(2):110-6. PubMed ID: 25483106
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing primary treatment of midline vulvar cancers.
Conrad LB; Conrad SA; Miller DS; Richardson DL; Kehoe S; Lea JS
Gynecol Oncol; 2016 Jul; 142(1):133-138. PubMed ID: 27132089
[TBL] [Abstract][Full Text] [Related]
13. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for recurrence and survival among patients with invasive vulvar Paget disease included in the VULCAN study.
Iacoponi S; Zalewski K; Fruscio R; Diaz-De la Noval B; De Iaco P; Ceccaroni M; Barazi D; Chen F; Zapardiel I;
Int J Gynaecol Obstet; 2016 Apr; 133(1):76-9. PubMed ID: 26861886
[TBL] [Abstract][Full Text] [Related]
15. [Recurrence of gynecologic malignancies after combined and primary radiotherapy. Incidence and lapse of time until the diagnosis is made].
Csaicsich P; Tatra G; Michalica W
Strahlenther Onkol; 1986 Jul; 162(7):409-13. PubMed ID: 3738739
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
17. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study.
Regauer S; Reich O; Eberz B
J Am Acad Dermatol; 2014 Oct; 71(4):698-707. PubMed ID: 24999271
[TBL] [Abstract][Full Text] [Related]
18. Association between invasive squamous cell carcinoma of the vulva and ABO blood group.
Redman R; Massoll NA; Wilkinson EJ
J Low Genit Tract Dis; 2005 Apr; 9(2):89-92. PubMed ID: 15870529
[TBL] [Abstract][Full Text] [Related]
19. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
